PDCD1 and neoplasm: A pre-clinical approach leverages the extensive availability of PD-L1 in the tumor microenvironment and employs NK cells equipped with a chimeric switch receptor linking PD-1 to activating domains CD3ζ, DAP10, or DAP12 (406).